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Abstract 
Aims: Postmenopausal women receive bisphosphonates for osteoporosis treatment. The effect of 
these medications on developing diabetes mellitus (DM) in prediabetic patients is yet to be 
investigated. We aimed to determine the effect of alendronate on plasma glucose, insulin indices of 
postmenopausal women with prediabetes and osteopenia. 
 
Methods: This triple-blind randomized controlled clinical trial included 60 postmenopausal women, 
aged 45–60 years. All patients were vitamin D sufficient. They were randomly enrolled in 
intervention (70 mg/week alendronate for 12 week) and control (placebo tablet per week for 12 
weeks) groups. The morning 8
 
hour fasting blood samples were collected at the baseline and follow–
up visits to measure the fasting plasma glucose (FPG) (mg/dl), insulin and hemoglobin A1c (HbA1c). 
Plasma glucose and insulin concentration were measured 30, 60, and 120 minutes after glucose 
tolerance test. Matsuda index, homeostasis model assessment of insulin resistance (HOMA–IR), 
homeostasis model assessment of beta–cell function (HOMA–B) and the area under the curves (AUC) 
of glucose and insulin were calculated. 
 
Results: Mean (SD) FPG (102.43 (1.46) mg/dl vs. 94.23 )1.17) mg/dl, P=0.001), 120-minutes insulin 
concentration (101.86 )15.70) mU/l vs. 72.60 (11.36), P=0.026), HbA1c (5.60 (0.06) % vs. 5.40 
(0.05)%, P=0.001), HOMA-IR (3.57 (0.45) vs. 2.62 (0.24), P=0.021) and Matsuda index (7.7 (0.41) 
vs. 9.2 (0.4), P=0.001) significantly improved in the alendronate-treated group. There was statistically 
significant more reductions in FPG (-8.2 (8.63) mg/dl vs. -2.5 (14.26) mg/dl, P=0.002) and HbA1c (-
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0.2 (0.23) % vs. -0.09 (0.26) %, P=0.015) were observed in alendronate-treated group than placebo 
group during the study course, respectively. 
 
Conclusions: Administration of 70 mg/week alendronate improves fasting plasma glucose, HbA1c 
and insulin indices in postmenopausal women. 
 
Keywords: Alendronate; Menopause; Prediabetic   
This trial was registered with IRCT. (no. IRCT2016101530309N1) 
 
Introduction 
Diabetes is a serious global health issue and is a major cause of morbidity, mortality, and 
worldwide economic burden with an annual increase in the prevalence rate
1
. Although the 
prevalence of diabetes mellitus (DM) among the Iranian population is close to the global 
prevalence (8–9%), it has increased to roughly 20% in women, aged 55–65 years2. Therefore, 
any method that can reduce the chance of developing DM in this high-risk group of women 
by paying more attention to prediabetic patients is highly desirable. 
 
DM is associated with increased prevalence of complications such as nephropathy, 
cardiomyopathy, retinopathy, and vasculopathy
3
, mainly caused by generalized capillary 
dysfunction
4
. Hence, several interventions have been suggested to reduce the incidence rate 
of DM, such as lifestyle or pharmacological interventions to reduce the risk factors
5,6
. The 
prediabetes is mainly diagnosed by impaired fasting glucose (IFG) and/or impaired glucose 
tolerance (IGT)
7
, defined by hemoglobinA1c (HbA1c) levels of 5.7%–6.4%3. Generally, 25–
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
50% of patients in the prediabetic state develop DM
8
, thus appropriate risk reduction methods 
and interventions in prediabetic state can prevent its progression to DM and assist in reducing 
diabetes–related complications9,10. 
 
Another significant and prevalent cause of morbidity and mortality in postmenopausal 
women is osteoporosis, characterized by substantial bone loss, resulting in increased risk of 
fractures
11
, that imposes a great cost and impairs the quality of life of the affected patients
12
. 
Bisphosphonates, specifically alendronate and risedronate
13
, are in the first line of treatment 
for osteoporosis with few adverse effects
14
 that efficiently suppress bone resorption and 
prevent fractures. Bisphosphonates have also shown antitumor effects
15
, and lipid profile 
modification
16
. Recent population–based studies have suggested 50% reduced risk of type 2 
diabetes mellitus (T2DM) with the use of bisphosphonate, but it has not yet been proven 
clinically
17,18
. Studies performed on mouse models have suggested that reduced bone 
turnover can regulate insulin sensitivity
19,20
, A population based cohort study indicated that 
the use of alendronate decreased the incidence of diabetes
21. 
However, no clinical trial study 
has yet investigated the effect of anti-resorptive therapies on fasting glucose, weight and 
diabetes incidence. The aim of the present study was to determine the effect of 
bisphosphonates on metabolic indices (FPG, Insulin, HOMA–IR, HOMA–B, Matsuda Index) 
of postmenopausal women with prediabetes and osteopenia. We opted for patients with 
osteopenia because it is unethical to deprive osteoporotic patients of proven treatment. 
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Materials and methods 
Study design 
The present triple–blind randomized controlled trial (RCT) was carried out in the Isfahan 
Endocrine and Metabolism Research Centre, Isfahan University of Medical Sciences, 
Isfahan, Iran, between 20 March 2016 and 21 December 2016. The study was approved by 
Ethics Committee of the Isfahan University of Medical Sciences (code: 
Ir.mui.rec.1395.3.292) and registered in the Iranian Registry of Clinical Trials (IRCT) (code: 
IRCT2016101530309N1). This study was performed in accordance with the ethical standards 
placed in the 1964 Declaration of Helsinki and its later amendments. Among all patients who 
were referred to the Isfahan Endocrine and Metabolism Research Center, 60 eligible 
postmenopausal women (amenorrhea for at least 12 months), aged 45–60, with prediabetes 
and osteopenia (bone densitometry with a T score of –1.5 to –2.4, diagnosed by dual-energy 
x-ray absorptiometry (DXA, Hologic 2008 model) and normal serum level of vitamin D were 
recruited (25 OHD>20 ng/ml). Those patients who had renal failure, unattended the follow–
up, received corticosteroid therapy or medications that affect carbohydrate or lipid 
metabolism including metformin, pioglitazone, statins, beta blockers, anti-inflammatory and 
ACE inhibitors, were excluded from the study.  The subjects were under surveillance 
throughout the entire study and were followed-up carefully. According to the patients' 
declarations, they took no additional medications without informing the research team, and 
patients who had to use other drugs at any time during the study were excluded. The sample 
size was determined to be 30 patients in each group based on previous studies, considering 10 
people for lost to follow up
22, with α=0.05, and β=80%. Eventually, 40 people were enrolled 
for the study. The patients’ enrollment diagram is shown in figure 1.  
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All participants were given an informed consent and randomized into intervention and 
placebo groups using block randomization method. The intervention group received 70 
mg/week alendronate (Dr. Abidi Company, Iran), and the control group received placebo 
(produced by the Pharmaceutical faculty of the Isfahan University of Medical Sciences in the 
same size, shape, and color). The Pharmaceutical faculty allocated codes of A and B to these 
medications and revealed the codes to the research team after completion of the clinical 
study. One tablet per week for 12 weeks was prescribed for patients to take in the morning 
while fasting with a glass of water in the non-supine position for at least an hour after taking 
the tablet. The patients were randomly assigned to treatment arms on a 1:1 basis to receive 
alendronate or placebo. The research team members who were recording the data, the 
physicians examined the patients, and the person who was giving medications to the patients 
with codes A and B according to the randomization block groups, were all blind to the group 
allocations. A member of the research team contacted subjects every 2 weeks in order to 
make sure the use of pills by patients, therefore the included subjects that completed the 
study protocol had complete adherence to the medications. Two blood samples were 
collected from each participant at the baseline and at the end of the follow-up period; 
following 8 hours of overnight fasting to measure the fasting plasma glucose, insulin, HbA1c, 
and 25 hydroxy vitamin D3 [25(OH) D3]. The glucose tolerance test was performed by using 
75 g glucose, the blood samples were collected before and after 30, 60, and 120 minutes to 
measure plasma glucose and insulin. Insulin sensitivity, and resistance were calculated from 
Matsuda index and homeostasis model assessment of IR (HOMA IR), respectively. The 
Matsuda index was calculated by: 10,000/square root of (fasting glucose [mg/dl] × fasting 
insulin [mIUl/l]) × [mean glucose [mg/dl] × mean insulin [mIUl/l] during oral glucose 
tolerance test (OGTT)] and HOMA- IR was defined as: (fasting glucose [mmol/ml] × fasting 
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insulin [mIUl/l])/22.5. B cell function was measured from HOMA B, defined as: 20 × fasting 
insulin [mIUl/l] /(fasting plasma glucose [mmol/ml] −3.5)23  
Plasma glucose levels were measured by Colorimetric Enzymatic Method using Photometric 
Single-Point Measurement. The insulin levels were measured by Sandwich chemiluminescent 
immune assay (DIAPLUS insulin–96 test; Siemens, Germany). Inter-assay coefficients of 
variations (CVs) were 0.9 for glucose and 1.9 for insulin and their intra-assay CVs were 1.5 
and 2.53, respectively. HbA1c was measured using Chromatography Ion Exchange approach. 
Vitamin D (25 OH D) concentration was assessed by direct competitive chemiluminescent 
immunoassay (IDS, Boldons, UK).  
 
Statistical Analysis 
The continuous quantitative variables are reported as means and standard errors (SE) or 
median (interquartile rang (IQR)). Normality of data was evaluated using the Kolmogorov-
Smirnov test and Q-Q plot. Log transformation was used for all positive skewed data 
including HbA1c, HOMA-IR. Independent samples t-test was used for comparing the 
quantitative baseline data between two groups. In order to detect within–group differences in 
the biochemical characteristics, paired samples t–test was used and analysis of covariance 
(ANCOVA) was performed to determine the differences between two groups, adjusted by 
baseline values. The changes in glucose and insulin concentrations (obtained during the 2–
hour OGTT) were evaluated using repeated measures analysis of variance (ANOVA). All 
experimental data were analyzed using the Statistical Package for the Social Sciences (SPSS) 
(version 20, SPSS Inc., Chicago, IL, USA). 
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Results 
This study was carried out between 20
th
 March 2016 and 21
st
 December 2016 on women with 
osteopenia and prediabetes states. A total of 20 participants, 10 patients from placebo–treated 
(poor compliance, n=10; lost to follow up, n=0) and 10 patients from the 70 mg alendronate–
treated (poor compliance, n=5; lost to follow up, n=5) group were excluded. Finally, 60 
patients (Placebo–treated group, n = 30; 70 mg alendronate–treated group, n = 30) completed 
the trial (Figure 1). The excluded participants were compared with those who completed the 
study on available data for HbA1c and FBS, and no significant differences were detected.  
Baseline characteristics of patients are presented in Table 1. Participants of both groups were 
similar according to demographic and anthropometric characteristics, serum measurements 
and laboratory data including 25OH (D)3 concentration (P > 0.05) at baseline.  
A significant decrease was found in FPG, HbA1c and an increase in Matsuda index (P < 
0.001), insulin of 120 minutes, and HOMA-IR (P<0.05) in the alendronate–treated group 
after intervention (Table 2). At the end of the study, the mean of fasting plasma glucose and 
HbA1c were statistically different between alendronate– and placebo–treated groups. The 
same outcomes were obtained between two groups following adjustment of baseline values 
for biochemical characteristics with ANCOVA. We have also observed statistically 
significant reductions of FPG (-8.2 (8.63) mg/dl vs. -2.5 (14.26) mg/dl, P=0.002) and HbA1c 
(-0.2 (0.23) % vs. -0.09 (0.26) %, P=0.015) in alendronate-treated group compared to 
placebo-treated group during the course of the study.  
The mean (SE) of plasma glucose and insulin levels during OGTT in the patients before and 
after intervention (administration of alendronate and placebo) are shown in figures 2 and 3, 
respectively. The cubic trend was detected and statistically significant differences in plasma 
glucose over time at all measured points (30, 60, and 120 minutes during the OGTT) were 
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observed in 70 mg alendronate–treated group. These changes in alendronate treated patients 
were significantly higher than placebo-treated group [F (1,58) = 4.433, p–value = 0.04]. The 
changes in plasma insulin concentrations of alendronate-treated patients were statistically 
insignificant over the time points of OGTT (30, 60, and 120 minutes). The mean of plasma 
glucose and insulin levels remained unchanged in the placebo-treated participants during 
OGTT. 
 
Discussion 
The primary aim of the present RCT study was to investigate the effect of alendronate on 
plasma glucose, insulin levels, sensitivity and resistance indices during an oral glucose 
tolerance test (OGTT) among osteopenic prediabetic postmenopausal women. We have found 
an 8.2 mg/dl decrease in FPG and 0.2% in HbA1c among alendronate-treated group, which 
remained statistically significant after adjustment for confounding variables in the 
intervention group, whereas the changes were not significant in the control group. These 
results suggest that 70 mg/week oral alendronate for 12 weeks can significantly improve FPG 
and HbA1C levels of prediabetes postmenopausal women and might slow down the rate of 
progression to diabetes. 
The comparison of the results of plasma glucose (OGTT) before and after intervention 
indicated a statistically significant decrease in plasma glucose in 70 mg alendronate–treated 
group at all intervals (30, 60, and 120 minutes during the OGTT), as well as significant 
difference with the placebo group. These results are similar to the observational studies 
indicating lower incidence of T2DM in patients receiving bisphosphonates
17,18
 and the 
present RCT confirmed lower plasma glucose levels in OGTT by alendronate. A cohort study 
in Denmark
18
 reported reduced developing rate of T2DM in patients taking medications 
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(alendronate, etidronate, and raloxifene) for osteoporosis with non-diabetic control subjects 
and noted a dose–dependent risk reduction for alendronate. More than a year of exposure in 
individuals older than 60 years without diabetes at the baseline to bisphosphonates (including 
alendronate, risedronate, etidronate, zoledronate, and ibandronate), reduced the risk of DM 
(OR= 0.52), compared to general matched unexposed individuals in a retrospective 
population–based study17. A significantly higher incidence of DM (OR=1.21) is also reported 
in the control group compared to alendronate-treated osteoporotic patients without DM in a 
retrospective cohort study
21
. This incidence rate was statistically significant among patients 
younger than 65 years and those without hypertension or dyslipidemia
21
. Although the results 
of previous studies are in agreement with the present report, our group is specifically 
included prediabetes and postmenopausal women. We have measured FPG, HbA1C, HOMA-
IR index, and Matsuda index and compared two randomized groups with similar baseline 
characteristics, despite healthy individuals who were chosen for the control groups in 
previous reports
 17,18,21
.  
The present study is the first report on evaluating the effect of alendronate on serum glucose 
and insulin parameters (FPG, insulin, HOMA–IR, HOMA–B, and Matsuda Index) of patients 
with osteopenia and prediabetes. Animal studies have shown that insulin signaling in 
osteoblasts promotes glucose metabolism in a bone resorption–dependent manner19,20, 
prevent insulin resistance and diabetes, and regulate glucose metabolism through alterations 
in bone metabolism and fat mass
24
, suggesting bone as an endocrine regulator for glucose 
metabolism
25,26
. In addition, the effect of bisphosphonates on early diabetes-associated bone 
loss has been confirmed in rodent models
27,28
. Decarboxylation of osteocalcin produced by 
osteoblasts due to unknown factors, results in its activation. Osteocalcin interacts with insulin 
receptor of the pancreas B-cells, leading to altered glucose metabolism
19
 and regulate the 
expression of the insulin genes and cell proliferation markers in rat models
24
. We anticipate 
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that alendronate influence glucose metabolism through the above-mentioned mechanisms, as 
well as disruption of prenylation of small molecular mass G-proteins and pro-inflammatory 
cytokines or mutations in gastric inhibitory polypeptide receptors
29,17
. Further evidence on 
human have reported improved bone health by bisphosphonates in postmenopausal women 
with T2DM
30,31
, but could not confirm the effect of bisphosphonates on osteocalcin and 
insulin metabolism 
32
, which is in agreement with the present study, indicating no significant 
difference in plasma insulin levels between 70 mg alendronate–treated group and the control 
group. We have shown that bisphosphonates may prevent progression of prediabetes to DM 
in postmenopausal patients. 
The major strength of the present study includes designing a well-controlled triple-blind 
clinical trial, which compares two randomized groups with parallel baseline characteristics, 
while previous studies had mainly evaluated participants in a retrospective design. We have 
also investigated the serum variables to assess diabetes–related indices (FPG, Insulin, 
HOMA–IR, HOMA–B, Matsuda Index), among postmenopausal prediabetic women with a 
high risk of developing DM and osteoporosis, while previous reports studied the general 
population.  
On the other hand, the present study had some limitations, including the small sample size in 
each group, which could explain the non-significant differences between groups. We detected 
no significant differences between available characteristics of excluded patients compared to 
those who completed the study, however, this comparison was made based on limited data. 
Although 30 subjects are statistically sufficient to achieve reliable results, it is suggested that 
future multicentric studies address the same population with a larger sample size. 
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Administration of 70 mg/week alendronate has significantly reduced FPG, HbA1C, HOMA-
IR index, and increased Matsuda index in postmenopausal women with prediabetes and 
osteopenia, while there was significant difference only in terms of FPG and HbA1c between 
the two groups at the end of study. This indicates positive effect of alendronate on diabetes 
related indices, specifically FPG and HbA1c.  
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A list of supporting information 
Appendix S1: CONSORT 2010 check list of information to include when reporting a 
randomized trial 
 
Figure legends 
Figure 1. Consort Flow diagram for enrollment of participants in the study 
Figure 2. The effect of Alendronate and placebo on plasma glucose during oral glucose 
tolerance test (OGGT) before and after intervention in both groups 
*P–value < 0.05 in comparison between before and after treatment by 70 mg Alendronate 
(cubic –trend) at all measured time points 
Figure 3. The effect of Alendronate and placebo on plasma insulin levels during oral glucose 
tolerance test (OGGT) before and after intervention in both groups 
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Table 1. Baseline characteristics of 70 mg Alendronate–and Placebo–treated patients  
Characteristics Alendronate 
treated (n=30) 
Placebo  
treated (n=30)   
P–value* 
Age (years) 56.5(6.3) 55.3(4.0) 0.406 
Height (cm) 160.33(1.07) 161.80(1.10) 0.344 
Weight (kg) 68.5(9.3) 68.3(9.4) 0.912 
Body mass index (kg/m
2
) 26.6(3.1) 26.0(3.0) 0.449 
Waist circumference (cm) 84.0(9.5) 81.5(10.9) 0.346 
Systolic Blood Pressure (mmHg) 129.7(14.0) 128.3(15.8) 0.731 
Diastolic Blood Pressure (mmHg) 69.4(18.1) 71.0(18.9) 0.728 
        *Resulted from Independent sample t-test 
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Table 2. Serum measurements before and 12 weeks after intervention in study groups 
 Alendronate treated (n=30)   Placebo treated (n=30)   
Variables  Before  After  P* Mean 
difference 
(SE)
 
 
  Before  After  P* Mean 
difference 
(SE)
 
 
 P** 
FPG
b
(mg/dl)
 102.4(1.46) 
[101.5(96.8-107.2)] 
94.2(1.17) 
[95(90.5-98.2)] 
<0.001 -8.2(8.63)  106.4(1.98) 
[105(99-115.22)] 
103.9(2.31) 
[102(95-113)] 
0.345 -2.5(14.26)  0.002 
FPI
a
( mU/l)
 13.87(1.60) 
 
11.3(1.05) 0.065 -2.56(7.33)  15.33(4.10) 15.63(4.09) 0.949 0.3(25.6)  0.327 
Hb A1C
c
 (%) 5.60(0.06) 
[5.55(5.4-5.8)] 
 
5.40 (0.05) 
[5.4(5.25-5.5)] 
<0.001 -0.2(0.23)  5.77(0.07) 
[5.75(5.48-5.03)] 
5.68(0.08) 
[5.65(5.3-6)] 
0.070 -0.09(0.26)  0.015 
25OH(D)3(ng/ml) 80.47(9.06) 
 
85.17(7.46) 0.433 4.70(32.39)  95.27(12.18) 104.87(11.73) o.289 9.6(48.7)  0.314 
HOMA–IR 3.57(0.45) 
[2.76(1.87-4.4)] 
 
2.62(0.24) 
[2.44(1.54-3.19)] 
0.021 -0.95(2.12)  4.19(0.66) 
[3.12(2.31-4.95)] 
4.11(1.11) 
[2.79(1.72-3.9)] 
0.951 -0.08(7.26)  0.203 
HOMA –B 124.30(12.50) 
 
136.3(15.05) 0.353 12(69.6)  122.96(12.50) 139.23(31.90) 0.632 16.27(184.3)  0.920 
AUC (glucose) 927.72(47.49) 
 
864.86(28.64) 0.113 -62.86(169)  1000.44(39.40) 960.33(45.47) 0.289 -40.11(203.4)  0.165 
AUC(insulin)  488.72(75.6) 
 
474.24(2.7) 0.144 -14.48(52.85)  489.54(13.8) 475.88(15.44) 0.403 -13.65(88.1)  0.944 
Matsuda Index 7.7(0.41) 
[7.67(6.07-9.31)] 
 
9.2(0.41) 
[8.71(7.62-10.96)] 
<0.001 1.45(2.3)  7.3(45) 
[7.21(5.77-8.37)] 
8.3(41) 
[8.15(6.74-10.39)] 
0.100 0.93(2.9)  0.166 
 
Abbreviations: BMI, body mass index; AUC, area under curve; 25OH(D)3, 25 hydroxy vitamin D3; HOMA–IR, homeostasis model assessment of insulin 
resistance; HOMA –B, homeostasis model assessment of beta–cell function 
 
Values are shown as means and standard error (SE) and [median(Interquartile rang(IQR)];* Obtained from paired samples test; ** Obtained 
from ANCOVA after adjusting baseline values. 
a
 :Fasting Plasma insulin 
b
: Fasting plasma glucose 
c
: Hemoglobin A1C 
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